Furthermore, both prescribing physician & psychiatrist, failed to counsel patient
& caregivers to immediately report signs of potential CVAEs such as sudden
weakness or numbness in the face, arms or legs, and speech or vision problems.
According to the
The Compendium of Pharmaceuticals and Specialties: The Canadian
for Health Professionals, (CPS), Zyprexa (Olanzapine) has no proven
benefit to elderly dementia patients.
2) Another physician, who is based in Smoky Lake, signed a Death Certificate, cited
the cause of death, yet never had assessed the patient or ever saw the patient prior
to death. At no time did he view or identify the body. The same physician could
not recall the nursing staff who had called him concerning the decedent.
3) An R.N. reported that after a diagnosis of Norwalk virus, no chart entries were
made in the patient’ file for an entire week. Intake and out put was not recorded.
*Eli Lilly Canada Inc., following discussions with Health Canada, would like
you of important new safety information
cerebrovascular adverse events,
dementia-related psychosis treated with
ZYPREXA (olanzapine) in clinical trials.
ZYPREXA is not approved for use in elderly patients with dementia-related